In a retrospective analysis of two different trials of patients with melanoma treated with anti-CTLA-4 ± anti-PD1 ICI, HLA I expression was a reliable marker of response to anti-CTLA-4 ICI, but not to anti-PD1 ICI [45]. Here, CTLA4 is linked to melanoma.